CD80 and neoplasm: Despite the generally accepted concept that anti-mouse CTLA-4 mAbs induce tumor rejection by blocking negative signaling from the B7-CTLA-4 interaction, the blocking activity of these antibodies4–6,9–11 have not been critically evaluated.